Boston Therapeutics, a company focusing on the development of diabetes treatments using complex carbohydrate chemistry, continues to make progress in raising public awareness of its diabetes drug’s potential. The company announced in a news release today it will be presenting … Continue reading →

Boston Therapeutics, a company focusing on the development of drugs using complex carbohydrate chemistry to address diabetes, reported in a news release today it is an exhibitor at the inaugural Obesity Week 2013 Conference in Atlanta, Georgia. The conference, taking … Continue reading →

Boston Therapeutics announced it has begun enrolling patients in a Phase 2b Trial for its PAZ320 drug today. A total of 24 patients with type 2 diabetes currently being treated with metformin will be administered PAZ320 under double-blind, placebo-controlled conditions. … Continue reading →

Boston Therapeutics today announces it will be making a presentation on a corporate update at the Livingston Securities Advanced and Nano Life Sciences Summit. The presentation is to be given by the President of Boston Therapeutics, Kenneth A. Tassey, Jr., … Continue reading →

Boston Therapeutics today announces it has initiated a research study with the University of Minnesota on PAZ320, a complex carbohydrate-based drug designed to reduce the elevation of post-meal blood glucose by blocking the action of carbohydrate-hydrolyzing enzymes. Entitled “NMR studies … Continue reading →

A recent BiotechStockTrader.com article (http://dtg.fm/SyR6), highlighting the unique and positive position that Boston Therapeutics now holds with regard to the multi-billion dollar diabetes drug industry, laid out the reasons why investors are starting to jump on board the still small … Continue reading →

Boston Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs. An IP portfolio solidifies the company’s position in the pharmaceutical industry. Boston Therapeutics’ current product … Continue reading →